Crossref
What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses
Transfuze a hematologie dnes · 10.03.2026 · 32 (1)
DOI: 10.48095/cctahd202605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfuze a hematologie dnes, online erschienen am 06.03.2026. Verfasst von Lubomír Minařík.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Minařík, L. (2026). What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses. Transfuze a hematologie dnes, 32(1). https://doi.org/10.48095/cctahd202605
Vancouver
Minařík L. What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses. Transfuze a hematologie dnes. 2026;32(1). doi:10.48095/cctahd202605
BibTeX
@article{Minak2026,
author = {Minařík, Lubomír},
title = {What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses},
journal = {Transfuze a hematologie dnes},
year = {2026},
volume = {32},
number = {1},
doi = {10.48095/cctahd202605}
}
EUVIMED